Strides Pharma reports Rs. 24,897 million revenue during FY26, 2% YoY growth
Ex-US revenue rose sharply by 21% YoY to Rs. 22,404 million ($254 million); Operational PAT grew 50.3% YoY to Rs. 5,181 million
Ex-US revenue rose sharply by 21% YoY to Rs. 22,404 million ($254 million); Operational PAT grew 50.3% YoY to Rs. 5,181 million
Mahatma Gandhi Cancer Hospital & Research Institute has emerged as the leading provider of comprehensive cancer care in Viza
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Subscribe To Our Newsletter & Stay Updated